Rapid clinical impact ART-Plan, a dedicated radiotherapy suite trusted by over 60 cancer centres across multiple regions and benefiting more than 60,000 patients annually, indicates a strong track record and potential for expansion with new oncology-focused deployments and service offerings.

AI driven partnerships TheraPanacea leverages proprietary AI platforms in close collaboration with leading healthcare facilities, signaling opportunities to co-develop or white-label AI solutions for additional medical domains and higher-tier hospital networks.

Clinical workflow integration ART-Omics enables multi-modality biomarker discovery integrated into clinical trial workflows, presenting a sales angle for pharmaceutical companies seeking scalable AI-enabled trial data workflows and certified medical device compliance.

Global market reach Presence spanning Europe, Africa, the Middle East, and the US suggests potential for regional partnerships, EUR/USD pricing strategies, and tailored regulatory navigation to accelerate market entry for new AI healthcare solutions.

Medium sized growth With 51-200 employees and revenue in the 10–25 million range, TheraPanacea sits between boutique AI health tech and larger diagnostics firms, offering opportunities to upsell managed services, and scaled deployments to mid- to large-size hospital networks and pharma clients.